Business Context and Reporting Period
This Form 8-K filing by LabStyle Innovations Corp. (not Dariohealth Corp.) reports a corporate event occurring on March 16, 2015, with the report filed on March 20, 2015. The Company, incorporated in Delaware and based in Israel, announced the second closing of a private placement offering of units.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $400,000 raised in this specific closing.
- Securities Issued: 2,222,222 shares of Common Stock and warrants exercisable for an aggregate of 1,111,112 shares.
- Purchase Price: $0.18 per unit.
- Unit Composition: One share of Common Stock plus two warrants (0.25 Series A and 0.25 Series B per unit).
- Warrant Terms:
- Series A: Exercise price $0.24; expires 9 months from closing.
- Series B: Exercise price $0.30; expires 36 months from closing; callable if stock trades over $0.80 for 20 consecutive days.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt, as this is a transactional report rather than a financial statement.
Material Changes and Agreements
The primary material change is the capital raise via the second closing of the Offering. Two accredited investors participated, including a private investment fund managed by Prof. Richard Stone (a Company director) and an individual with a pre-existing relationship to Prof. Stone. The Company also entered into a Registration Rights Agreement, obligating it to file a registration statement for the resale of shares within 60 days of the initial closing and to use reasonable best efforts to have it declared effective within 75 days (or 150 days if reviewed by the SEC).
Outlook, Risks, and Contingencies
- Registration Obligations: The Company faces potential liquidated damages if it fails to meet the registration filing and effectiveness deadlines outlined in the Registration Rights Agreement.
- Call Provision: The Series B Warrants are subject to a call provision if the Common Stock price exceeds $0.80 for 20 consecutive trading days.
- Exemptions: The securities were issued under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, relying on the absence of a public offering and the accredited status of investors.
Investor Verification Checklist
- Verify the total aggregate proceeds raised across both the February 25 and March 16 closings.
- Confirm the status of the registration statement filing required within 60 days of the initial closing to assess potential liquidated damages.
- Review the Company's current cash position to determine the runway provided by the $400,000 gross proceeds.
- Check for any subsequent filings regarding the effectiveness of the registration statement or the exercise of the call option on Series B Warrants.